Blog Detail
Zamp Bionews
http://bionews.zampbioworld.org
Zamp bionews is one part of Zamp BioWorld. Zamp BioWorld offers Bio Tools, Bio News, Bio Materials, Bio Videos, Bio Links, Bio Topics, Wiki, Bio Glossary and much more
Recent Posts
Abbott To Develop New Heart Failure Test On ARCHITECT® Immunochemistry Diagnostics Platform
Abbott (NYSE: ABT) and BG Medicine, Inc. announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abb...
AstraZeneca Submits US New Drug Application For Brilinta (Ticagrelor), An Investigational Antiplatelet Agent
AstraZeneca announced it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute c...
European Medical Advisory Committee Does Not Recommend Approval Of Avastin For Deadly Form Of Brain Cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the Committee for Medicinal Products for Human Use (CHMP), which is responsible for conducting the initial assessment of medicinal products that have been filed for marketing authorisation in Europe, ...
Sanofi-aventis And Medicines For Malaria Venture To Launch The Largest Ever Study Of An Antimalarial Drug
Sanofi-aventis ( EURONEXT: SAN and NYSE: SNY) and Medicines for Malaria Venture (MMV) announced that they have entered an agreement to launch the largest safety and efficacy study of an antimalarial drug. This field-monitoring program on ASAQ, a fixe...
Novartis Influenza A(H1N1) 2009 Vaccine US Interim Data Show Lower Doses Of Antigen May Suffice To Generate A Protective Immune Response
Novartis announced new interim data from ongoing clinical trials demonstrating that a single 7.5µg dose of the company’s influenza A(H1N1) 2009 unadjuvanted vaccine, half of the currently-approved US dose, fulfilled immune response criteria as...
Merck KGaA: CHMP Opinion For Erbitux In Advanced Non-Small Cell Lung Cancer
The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has adopted a negative opinion for the use of Erbitux® (cetuximab) in combination with platinum-based chemotherapy for the t...


I think the author has worked really hard to make available such a fantastic with useful articles on Bio.
Well done.
Posted: May 8th, 2009 | More Reviews From PearlTrader | Report This Comment